| Molecular Interaction Atlas (MIA) |
|
| Indication(s) of Uracil mustard |
| Disease Entry |
ICD 11 |
Status |
REF |
| Acute myeloid leukaemia |
2A60
|
Approved |
[2] |
| Chronic myelogenous leukaemia |
2A20.0
|
Approved |
[3] |
| Polycythemia vera |
2A20.4
|
Approved |
[3] |
| Small lymphocytic lymphoma |
2A82.0
|
Approved |
[3] |
|
|
|
Uracil mustard Interacts with 1 DTT Molecule(s)
| DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
|
Human Deoxyribonucleic acid (hDNA)
|
TTUTN1I
|
NOUNIPROTAC
|
Modulator
|
[5] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
Uracil mustard Interacts with 2 DOT Molecule(s)
| DOT Name |
DOT ID |
UniProt ID |
Mode of Action |
REF |
|
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1)
|
OT7FBG5W
|
NAR1_HUMAN
|
Increases ADR
|
[6] |
|
Poly polymerase 1 (PARP1)
|
OTIESHK4
|
PARP1_ARATH
|
Increases ADR
|
[6] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
| Indication(s) of 10-hydroxycamptothecin |
| Disease Entry |
ICD 11 |
Status |
REF |
| Discovery agent |
N.A.
|
Investigative |
[4] |
|
|
|
10-hydroxycamptothecin Interacts with 1 DTT Molecule(s)
| DTT Name |
DTT ID |
UniProt ID |
Mode of Action |
REF |
|
DNA topoisomerase I (TOP1)
|
TTGTQHC
|
TOP1_HUMAN
|
Inhibitor
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
10-hydroxycamptothecin Interacts with 1 DTP Molecule(s)
| DTP Name |
DTP ID |
UniProt ID |
Mode of Action |
REF |
|
Multidrug resistance-associated protein 4 (ABCC4)
|
DTCSGPB
|
MRP4_HUMAN
|
Substrate
|
[7] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
10-hydroxycamptothecin Interacts with 1 DOT Molecule(s)
| DOT Name |
DOT ID |
UniProt ID |
Mode of Action |
REF |
|
Bcl-2-like protein 1 (BCL2L1)
|
OTRC5K9O
|
B2CL1_HUMAN
|
Decreases Response To Substance
|
[8] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
|
|
|
|
|
|
|
|